Paul Matte: Proud to present our work at ESMO TAT 2025
Paul Matte, Member of the ITO Editorial Board, shared a post on LinkedIn:
“Proud to present our work at ESMO TAT 2025 in Paris!
Today, I had the privilege of presenting our poster on «Renal function-based exclusion criteria in early-phase oncology clinical trials, the EXKID study».
Chronic kidney disease remains a frequent exclusion criterion in early-phase trials, often due to pharmacokinetic and safety concerns. Our study highlights the prevalent use of outdated renal function assessment methods, such as Cockcroft-Gault, despite its well-known limitations—particularly in patients with altered body composition (e.g., cancer-related cachexia).
We advocate for the adoption of more precise renal function estimation methods, like cystatin C-based clearance, to improve patient safety, drug dosing, and trial inclusivity.
A huge thank you to Matthieu Delaye, Matthieu Roulleaux Dugage and Christophe Massard for their invaluable contributions to this study.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023